Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 10

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Clin Oncol. Oct 10, 2012; 3(10): 137-141
Published online Oct 10, 2012. doi: 10.5306/wjco.v3.i10.137

Full Size Figure Download Figure

Figure 1 Waterfall plot showing maximum percent decrease in Ca-125 level.

Citation: Grenader T, Rosengarten O, Isacson R, Plotkin Y, Gabizon A. Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. World J Clin Oncol 2012; 3(10): 137-141
URL: https://www.wjgnet.com/2218-4333/full/v3/i10/137.htm
DOI: https://dx.doi.org/10.5306/wjco.v3.i10.137

Grenader T, Rosengarten O, Isacson R, Plotkin Y, Gabizon A. Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin. World J Clin Oncol 2012; 3(10): 137-141 [PMID: 23198277 DOI: 10.5306/wjco.v3.i10.137]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.